title: [PD-L1 expression: An emerging biomarker in non-small cell lung cancer].
abstract: Therapies targeting immune checkpoints, in particular programmed death 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1), are major new strategies for the treatment of several malignancies including mestatatic non-small cell lung cancer (NSCLC). The identification of predictive biomarkers of response is required, considering efficacy, cost and potential adverse events. Expression of PD-L1 by immunohistochemistry has been associated with higher response rate and overall survival in several clinical trials evaluating anti-PD-1 and anti-PD-L1 monoclonal antibodies. Thus, PD-L1 immunohistochemical companion assays could be required for treatment with some of these therapies in NSCLC. However, heterogeneity in methodologies of PD-L1 assays in terms of primary antibodies and scoring algorithms, and tumor heterogenity for PD-L1 expression are important issues to be considered. More studies are required to compare the different assays, ensure their harmonization and standardization and identify the optimal conditions for testing. PD-L1 expression is likely an imperfect predictive biomarker for patient selection and association with other markers of the tumor immune microenvironment will be probably necessary in the future.
authors.affiliation: Département de biologie et pathologie médicales, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Inserm U981, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France. Electronic address: julien.adam@gustaveroussy.fr.
authors.forename: Julien
authors.initials: J
authors.lastname: Adam
authors.affiliation: Département de biologie et pathologie médicales, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Département de médecine, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France.
authors.forename: David
authors.initials: D
authors.lastname: Planchard
authors.affiliation: DITEP Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Inserm U1015, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France.
authors.forename: Aurélien
authors.initials: A
authors.lastname: Marabelle
authors.affiliation: Inserm U981, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; DITEP Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Faculté de médecine, université Paris Saclay, 63, rue Gabriel-Péri, 94276 Le Kremlin-Bicêtre cedex, France.
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
authors.affiliation: Département de biologie et pathologie médicales, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Faculté de médecine, université Paris Saclay, 63, rue Gabriel-Péri, 94276 Le Kremlin-Bicêtre cedex, France.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Scoazec
authors.affiliation: Département de biopathologie, MESOPATH, centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France; Université Joseph-Fourier, Inserm U823, institut Albert-Bonniot, Grenoble, France.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Lantuéjoul
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000918:Antibody Specificity; D060890:B7-H1 Antigen / Q000032:analysis* / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry* / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D002999:Clone Cells; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007124:Immunoenzyme Techniques; D007150:Immunohistochemistry / Q000379:methods; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000737:chemistry* / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D058990:Molecular Targeted Therapy
chemical_list: D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; C423236:CD274 protein, human
keywords: Biomarqueur prédictif; Cancer immunotherapy; Carcinome pulmonaire non à petites cellules; Immunothérapies anti-tumorales; Non-small cell lung cancer; PD-L1; Predictive biomarker